Sirtuin 3 deficiency does not alter host defenses against bacterial and fungal infections
| Autor: | Ciarlo, Eleonora, Heinonen, Tytti, Lugrin, Jerome, Acha-Orbea, Hans, Le Roy, Didier, Auwerx, Johan, Roger, Thierry |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2017 |
| Předmět: |
Mice
Knockout Thymocytes Science Macrophages Bacterial Infections Dendritic Cells Article Immunophenotyping Mice Mycoses Sirtuin 3 Host-Pathogen Interactions Medicine Animals Humans Bacterial Infections/genetics Biomarkers Dendritic Cells/immunology Dendritic Cells/metabolism Disease Resistance/genetics Host-Pathogen Interactions/genetics Macrophages/immunology Macrophages/metabolism Mycoses/genetics Sirtuin 3/deficiency Thymocytes/immunology Thymocytes/metabolism Disease Resistance |
| Zdroj: | Scientific reports, vol. 7, no. 1, pp. 3853 Scientific Reports Scientific Reports, Vol 7, Iss 1, Pp 1-10 (2017) |
| Popis: | Sirtuin 3 (SIRT3) is the main mitochondrial deacetylase. SIRT3 regulates cell metabolism and redox homeostasis, and protects from aging and age-associated pathologies. SIRT3 may drive both oncogenic and tumor-suppressive effects. SIRT3 deficiency has been reported to promote chronic inflammation-related disorders, but whether SIRT3 impacts on innate immune responses and host defenses against infections remains essentially unknown. This aspect is of primary importance considering the great interest in developing SIRT3-targeted therapies. Using SIRT3 knockout mice, we show that SIRT3 deficiency does not affect immune cell development and microbial ligand-induced proliferation and cytokine production by splenocytes, macrophages and dendritic cells. Going well along with these observations, SIRT3 deficiency has no major impact on cytokine production, bacterial burden and survival of mice subjected to endotoxemia, Escherichia coli peritonitis, Klebsiella pneumoniae pneumonia, listeriosis and candidiasis of diverse severity. These data suggest that SIRT3 is not critical to fight infections and support the safety of SIRT3-directed therapies based on SIRT3 activators or inhibitors for treating metabolic, oncologic and neurodegenerative diseases without putting patients at risk of infection. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|